Multimodality therapy for medulloblastoma. [Efficacy and complications]
- Roswell Park Memorial Inst., Buffalo, NY
Eight patients with recurrent medulloblastoma were treated with a chemotherapy regimen consisting of vincristine, BCNU, dexamethasone and intrathecal and intermediate dose intravenous methotrexate (500 mg/m/sup 2/). Five also received local low dose radiotherapy (RT). All 8 patients responded to treatment; 6 completely and 2 partially. These latter 2 were in their second and third recurrences. Three remain in remission. The median duration of response was 18.8 months, and median time from start of chemotherapy to death was 32 months using the Kaplan-Meier technique. In addition, 9 other patients with newly diagnosed medulloblastoma were treated with craniospinal radiation and the same adjuvant chemotherapy as above. The first 5 patients also received intraventricular methotrexate and/or intravenous BCNU during radiotherapy. The toxicity in the 5 patients was very severe. There were three toxic deaths, one death from cancer; one patient survives disease-free, but he is demented. With the discontinuance of intraventricular methotrexate and the postponement of myelosuppressive chemotherapy until after the completion of radiotherapy, the regimen has been well tolerated. All 4 patients treated this way remain alive, well, and disease-free at intervals up to 36 months. We conclude that recurrent medulloblastomas are sensitive to multiagent chemotherapy and that prolonged remissions may occur. With primary adjuvant chemotherapy, extreme caution with myelosuppressive drugs must be exercised during the period of craniospinal radiotherapy. We also do not recommend the use of intraventricular methotrexate. When these two criteria were followed, the preliminary results with adjuvant chemotherapy appear encouraging.
- OSTI ID:
- 5519023
- Journal Information:
- Cancer; (United States), Vol. 45:4
- Country of Publication:
- United States
- Language:
- English
Similar Records
No Salvage Using High-Dose Chemotherapy Plus/Minus Reirradiation for Relapsing Previously Irradiated Medulloblastoma
A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931)
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
BLOOD PLATELETS
DELAYED RADIATION EFFECTS
CEREBELLUM
CHEMOTHERAPY
RADIOSENSITIVITY EFFECTS
SIDE EFFECTS
TOXICITY
ENCEPHALITIS
RADIOINDUCTION
RADIOTHERAPY
BRAIN
CENTRAL NERVOUS SYSTEM
CHILDREN
DATA COMPILATION
ELECTRONS
FRACTIONATED IRRADIATION
ISOLATED VALUES
LOCAL IRRADIATION
LOW DOSE IRRADIATION
NEOPLASMS
PATIENTS
SPINAL CORD
ANIMALS
BIOLOGICAL EFFECTS
BIOLOGICAL MATERIALS
BIOLOGICAL RADIATION EFFECTS
BLOOD
BLOOD CELLS
BODY
BODY FLUIDS
DATA
DATA FORMS
DISEASES
ELEMENTARY PARTICLES
FERMIONS
INFORMATION
IRRADIATION
LEPTONS
MAMMALS
MAN
MATERIALS
MEDICINE
NERVOUS SYSTEM
NERVOUS SYSTEM DISEASES
NUCLEAR MEDICINE
NUMERICAL DATA
ORGANS
PRIMATES
RADIATION EFFECTS
RADIOLOGY
THERAPY
VERTEBRATES
560151* - Radiation Effects on Animals- Man
550603 - Medicine- External Radiation in Therapy- (1980-)